TY - JOUR T1 - Cost-effectiveness of COVID-19 vaccination in low- and middle-income countries JF - medRxiv DO - 10.1101/2021.04.28.21256237 SP - 2021.04.28.21256237 AU - Mark J. Siedner AU - Christopher Alba AU - Kieran P. Fitzmaurice AU - Rebecca F. Gilbert AU - Justine A. Scott AU - Fatma M. Shebl AU - Andrea Ciaranello AU - Krishna P. Reddy AU - Kenneth A. Freedberg Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/05/02/2021.04.28.21256237.abstract N2 - Despite the advent of safe and highly effective COVID-19 vaccines1–4, pervasive inequities in global distribution persist5. In response, multinational partners have proposed programs to allocate vaccines to low- and middle-income countries (LMICs)6. Yet, there remains a substantial funding gap for such programs7. Further, the optimal vaccine supply is unknown and the cost-effectiveness of investments into global vaccination programs has not been described. We used a validated COVID-19 simulation model8 to project the health benefits and costs of reaching 20%-70% vaccine coverage in 91 LMICs. We show that funding 20% vaccine coverage over one year among 91 LMICs would prevent 294 million infections and 2 million deaths, with 26 million years of life saved at a cost of US$6.4 billion, for an incremental cost effectiveness ratio (ICER) of US$250/year of life saved (YLS). Increasing vaccine coverage up to 50% would prevent millions more infections and save hundreds of thousands of additional lives, with ICERs below US$8,000/YLS. Results were robust to variations in vaccine efficacy and hesitancy, but were more sensitive to assumptions about epidemic pace and vaccination costs. These results support efforts to fund vaccination programs in LMICs and complement arguments about health equity9, economic benefits10, and pandemic control11.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by the National Institutes of Health (R37 AI058736-16S1). The findings and conclusions in this report are those of the authors and do not necessarily represent the official views of the US National Institutes of Health.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No primary data collection or human subjects interactions was conducted as part of this analysis.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThere are no original data generated as part of this study. All data are derived from published or publicly available data and referenced as such. Code data will be made available to any requesting party by contacting the corresponding author. ER -